Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review
Authors:
- Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
- Ana Luísa Guedes de França-E-SilvaAna Luísa Guedes de França-E-Silva
- Henrique Lima de OliveiraHenrique Lima de Oliveira
- Khissya Beatryz Alves de LimaKLKhissya Beatryz Alves de Lima
- Iane de Oliveira Pires PortoIPIane de Oliveira Pires Porto
- Thays Millena Alves PedrosoTPThays Millena Alves Pedroso
- Daniela de Melo e SilvaDaniela de Melo e Silva
- Aguinaldo F. FreitasAFAguinaldo F. Freitas
Open Access
- 28 May 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5855
Abstract
Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by cellular and metabolic dysfunction, with mitochondrial dysfunction playing a crucial role. Although the direct relationship between genetic mutations and mitochondrial dysfunction remains unclear, targeting mitochondrial dysfunction presents promising opportunities for treatment, as there are currently no effective treatments available for HCM. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews guidelines. Searches were conducted in databases such as PubMed, Embase, and Scopus up to September 2023 using “MESH terms”. Bibliographic references from pertinent articles were also included. Hypertrophic cardiomyopathy (HCM) is influenced by ionic homeostasis, cardiac tissue remodeling, metabolic balance, genetic mutations, reactive oxygen species regulation, and mitochondrial dysfunction. The latter is a common factor regardless of the cause and is linked to intracellular calcium handling, energetic and oxidative stress, and HCM-induced hypertrophy. Hypertrophic cardiomyopathy treatments focus on symptom management and complication prevention. Targeted therapeutic approaches, such as improving mitochondrial bioenergetics, are being explored. This includes coenzyme Q and elamipretide therapies and metabolic strategies like therapeutic ketosis. Understanding the biomolecular, genetic, and mitochondrial mechanisms underlying HCM is crucial for developing new therapeutic modalities.Keywords
This publication has 117 references indexed in Scilit:
- Cardiac Remodeling in Subclinical Hypertrophic CardiomyopathyJAMA Cardiology, 2023
- CACNA1C-Related Channelopathies2023
- Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretideHeart Failure Reviews, 2020
- Hypertrophic Cardiomyopathy: The Future of TreatmentEuropean Journal of Heart Failure, 2020
- Energetic drain driving hypertrophic cardiomyopathyFEBS Letters, 2019
- Mutations inELAC2associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3′‐end processingHuman Mutation, 2019
- Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic CardiomyopathyJAMA Cardiology, 2019
- Gene therapy strategies in the treatment of hypertrophic cardiomyopathyPflügers Archiv - European Journal of Physiology, 2018
- Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individualsClinical Research in Cardiology, 2017
- Maternally Inherited Hypertrophic Cardiomyopathy: A Manifestation of Mitochondrial DNA Mutations—Clinical Course in Two FamiliesPediatric Cardiology, 2001